These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28123607)

  • 21. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
    BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
    Gogas H; Kotoula V; Alexopoulou Z; Christodoulou C; Kostopoulos I; Bobos M; Raptou G; Charalambous E; Tsolaki E; Xanthakis I; Pentheroudakis G; Koutras A; Bafaloukos D; Papakostas P; Aravantinos G; Psyrri A; Petraki K; Kalogeras KT; Pectasides D; Fountzilas G
    J Transl Med; 2016 May; 14(1):136. PubMed ID: 27184134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
    Fabi A; Metro G; Di Benedetto A; Nisticò C; Vici P; Melucci E; Antoniani B; Perracchio L; Sperduti I; Milella M; Cognetti F; Mottolese M
    Oncology; 2010; 78(2):141-9. PubMed ID: 20389136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
    Mercogliano MF; Inurrigarro G; De Martino M; Venturutti L; Rivas MA; Cordo-Russo R; Proietti CJ; Fernández EA; Frahm I; Barchuk S; Allemand DH; Figurelli S; Deza EG; Ares S; Gercovich FG; Cortese E; Amasino M; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    BMC Cancer; 2017 Dec; 17(1):895. PubMed ID: 29281999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
    Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
    Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.
    Dey N; Sun Y; Carlson JH; Wu H; Lin X; Leyland-Jones B; De P
    Am J Cancer Res; 2016; 6(4):714-46. PubMed ID: 27186427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.
    Koo DH; Lee HJ; Ahn JH; Yoon DH; Kim SB; Gong G; Son BH; Ahn SH; Jung KH
    Tumour Biol; 2015 Aug; 36(8):5865-71. PubMed ID: 25725586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
    BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
    Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
    Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations.
    Chung WP; Huang WL; Lee CH; Hsu HP; Huang WL; Liu YY; Su WC
    Am J Cancer Res; 2022; 12(7):3067-3082. PubMed ID: 35968355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients.
    Cao GD; Chen K; Chen B; Xiong MM
    BMC Cancer; 2017 Dec; 17(1):841. PubMed ID: 29233126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic role of lymphatic vessel density and lymphovascular invasion in chemotherapy-naive and chemotherapy-treated patients with invasive breast cancer.
    Niemiec JA; Adamczyk A; Ambicka A; Mucha-Małecka A; Wysocki WM; Biesaga B; Ziobro M; Cedrych I; Grela-Wojewoda A; Domagała-Haduch M; Wysocka J; Ryś J; Sas-Korczyńska B
    Am J Transl Res; 2017; 9(3):1435-1447. PubMed ID: 28386369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
    Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
    Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
    Lee HJ; Seo AN; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
    Br J Cancer; 2015 Jan; 112(1):103-11. PubMed ID: 25349977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.
    Kanomata N; Kurebayashi J; Moriya T
    Med Mol Morphol; 2019 Jun; 52(2):106-113. PubMed ID: 30317526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
    Tekesin K; Emin Gunes M; Bayrak S; Akar E; Ozturk T; Altinay S; Tural D
    J BUON; 2019; 24(5):1920-1926. PubMed ID: 31786856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.